Study of Pentoxifylline to Protect the Heart from Doxorubicin Side Effects in Women with Breast Cancer

What this Trial Is About

Researchers are evaluating the potential heart-protective effects of pentoxifylline in breast cancer patients receiving doxorubicin chemotherapy. This phase 2 clinical trial aims to compare changes in heart function, specifically ejection fraction, and blood markers related to heart stress and inflammation between patients receiving standard chemotherapy alone and those receiving chemotherapy plus pentoxifylline. The study addresses concerns about heart damage caused by doxorubicin treatment in breast cancer care. Participants will be randomly assigned to one of two groups one group will receive standard chemotherapy alone, and the other will receive standard chemotherapy combined with pentoxifylline at a dose of 400 mg taken orally three times daily with meals. The study lasts for at least three months during which the effects of pentoxifylline on chemotherapy-induced heart damage will be monitored. During the study, participants will undergo assessments including heart function tests to measure ejection fraction and blood tests to check levels of NT-pro-BNP and TNF-, which are indicators of heart stress and inflammation. These evaluations occur over a three-month period to track changes related to the treatments. Safety and overall health will be monitored throughout to understand the impact of adding pentoxifylline to chemotherapy in breast cancer patients.

Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients